Table 2.
Targeting therapeutic resistance with oridonin and its derivatives in vitro.
| aCell Lines Tested | Potential Mechanisms | Ref |
|---|---|---|
| Ovarian cancer A278/DDP and SKOV3/DDP cell lines | Induction of apoptosis, increase of cells in G0/G1 phase, downregulation of Bcl-2, upregulation of Bax, and decrease of MMP-2 and MMP-9 | 114 |
| Leukemia K562/ADR cell line | Upregulation of BIM-S by diminishing miRNA-7 and miRNA-20a | 118 |
| AML MV4-11/DDP and MOLM-13/DDP cell lines | Induction of apoptosis, inhibition of MMP-2 and MMP-9 | 115 |
| Renal cell carcinoma 786-O cell line | Induction of necrosis by depleting GSH and enhancing ROS. | 120 |
| Colorectal cancer HCT-15 and HCT-15/5FU-R cell line | Upregulation of ROS/JNK/c-Jun axis | 121 |
| Gastric cancer SGC7901/DDP cell line | Downregulation of P-gp, MRP1 and cyclin D1 | 110 |
| Pancreatic cancer PANC-1 (PANC-1/Gem) gemcitabine-resistant cell line | Inhibition of GST pi and LRP1/ERK/JNK signaling | 122 |
| NSCLC H1975-gefitinib-resistant cell line | Suppression of EGFR/ERK/MMP-12 and CIP2A/PP2A/Akt signaling pathways | 123 |
| Leukemia Ph+ (K562, KU812 and SUP-B15) cell lines | Depletion of BCR-ABL through activating HSF-1 for chaperone-mediated degradation | 126 |
| Leukemia imatinib-sensitive (K562–S) and imatinib-resistant (K562-R) cell lines | Downregulation of p-Lyn and inhibition of mTOR and Bcl-2 | 127 |